269 related articles for article (PubMed ID: 16622297)
1. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
Wake DJ; Walker BR
Endocrine; 2006 Feb; 29(1):101-8. PubMed ID: 16622297
[TBL] [Abstract][Full Text] [Related]
2. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
3. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Wake DJ; Walker BR
Mol Cell Endocrinol; 2004 Feb; 215(1-2):45-54. PubMed ID: 15026174
[TBL] [Abstract][Full Text] [Related]
4. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
Wake DJ; Rask E; Livingstone DE; Söderberg S; Olsson T; Walker BR
J Clin Endocrinol Metab; 2003 Aug; 88(8):3983-8. PubMed ID: 12915696
[TBL] [Abstract][Full Text] [Related]
5. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Walker BR; Andrew R
Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
[TBL] [Abstract][Full Text] [Related]
6. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.
Walker BR; Seckl JR
Expert Opin Ther Targets; 2003 Dec; 7(6):771-83. PubMed ID: 14640912
[TBL] [Abstract][Full Text] [Related]
7. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
9. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Sandeep TC; Andrew R; Homer NZ; Andrews RC; Smith K; Walker BR
Diabetes; 2005 Mar; 54(3):872-9. PubMed ID: 15734867
[TBL] [Abstract][Full Text] [Related]
10. [Modulation of tissue exposure to cortisol, new perspective for reducing the metabolic risk associated with obesity].
Iovino A; Scheen AJ
Rev Med Liege; 2010 Mar; 65(3):140-6. PubMed ID: 20411818
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
12. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
13. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Westerbacka J; Yki-Järvinen H; Vehkavaara S; Häkkinen AM; Andrew R; Wake DJ; Seckl JR; Walker BR
J Clin Endocrinol Metab; 2003 Oct; 88(10):4924-31. PubMed ID: 14557475
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
Seckl JR; Morton NM; Chapman KE; Walker BR
Recent Prog Horm Res; 2004; 59():359-93. PubMed ID: 14749510
[TBL] [Abstract][Full Text] [Related]
15. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Hughes KA; Webster SP; Walker BR
Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
[TBL] [Abstract][Full Text] [Related]
16. Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
Espíndola-Antunes D; Kater CE
Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1397-403. PubMed ID: 18209879
[TBL] [Abstract][Full Text] [Related]
17. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
Morton NM
Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
[TBL] [Abstract][Full Text] [Related]
18. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
19. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Morton NM; Paterson JM; Masuzaki H; Holmes MC; Staels B; Fievet C; Walker BR; Flier JS; Mullins JJ; Seckl JR
Diabetes; 2004 Apr; 53(4):931-8. PubMed ID: 15047607
[TBL] [Abstract][Full Text] [Related]
20. Diet and the role of 11beta-hydroxysteroid dehydrogenase-1 on obesity.
London E; Castonguay TW
J Nutr Biochem; 2009 Jul; 20(7):485-93. PubMed ID: 19443197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
